Call for Abstract
International Conference on Biomarkers and Clinical Research, will be organized around the theme “Awareness of Biomarkers & Clinical Research”
Biomarkers Congress-2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers Congress-2019
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Biomarker is a key molecular or cellular event that links a specific environmental exposure to a health outcome. Biomarkers can be all that can be appropriately measured as an indicator of normal biological working, pathogenic paths or a drug response to a therapeutic drug intervention. Biomarkers play a dynamic role in accepting the relationships between exposure to environmental chemicals, the development of chronic human diseases, and the identification of subgroups that are at increased risk for disease. Biomarkers are used in many specific fields.
- Regulatory validation
- Cell biology
- Geology and astrobiology
- Track 1-1Oncology biomarkers
- Track 1-2Cancer biomarkers
- Track 1-3Lipid biomarkers
- Track 1-4Cardiovascular biomarkers
- Track 1-5Neurological biomarkers
- Track 1-6Pathological biomarkers
Cardiac markers are dignified biomarkers to measure cardiac function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an elevation in the level of cardiac marker. Cardiac biomarkers are fundamentals that are released into the blood when the heart is injured or anxious. Cardiac marker is used in the identification and hazard stratification of patients with chest pain and suspected acute coronary syndrome (ACS). These markers include enzymes, hormones and proteins. Cardiac biomarkers have developed as important tools in cardiology in the last 50 years, that is, for primary and secondary prevention, the diagnosis and treatment of acute myocardial infarction (AMI), and the diagnosis and stratification of the risk of heart failure.
- Track 2-1Circulatory Biomarker
- Track 2-2Biomarkers for Heart Failure & Acute Coronary Syndrome
- Track 2-3Biomarkers for Metabolic Syndrome & Cardiovascular Risk
- Track 2-4Machine learning & Internet of Things (IoT) application in Digital Biomarkers
Neurological biomarkers are existing in the CSF (cerebrospinal fluid), but only at or gradually in the blood. The brain is carefully secure by the blood-brain barrier, which preserves it from harmful elements that flow into the circulation. Inappropriately for diagnostic purposes, this barrier has also made brain chemistry unfeasible for proper blood testing. Neurological biomarkers can be studied using CSF, but this involves an invasive and painful lumbar lesion technique.
- Track 3-1Biomarkers in Neuro-oncology Brain tumor & Brain damage
- Track 3-2Biomarkers for early identification of Neurological disorders
- Track 3-3Biomarkers in central nervous system diseases
- Track 3-4Personalized medicine and diagnostic in Neuro science
Present-day genomics and biotechnology potential the advance of biomarkers to a state to calculate the risk of individual disease that allows primary detection of the disease and improves diagnostic classification to better inform adapted treatment. Biomarkers are biological dimensions that can be used to calculate the risk of diseases, to allow early exposure of diseases, to improve the selection of treatment and to monitor the outcome of therapeutic interferences. The main purpose of the Human Genome Project was the documentation and enlargement of such biomarkers for "personalized, preventive and predictive medicine".
- Track 4-1Predictive Biomarkers to immunotherapies
- Track 4-2Biomarkers for precision immune-oncology
- Track 4-3Biomarkers in Immune monitoring
Biomarkers that can regulator several diseases of the immune system such as autoimmunity, immunodeficiency, cancer, allergies and infections are called immunological biomarkers. As the immune system interrelates with all other systems in the body, it theatres a very important role in the discovery of biomarkers. Immunological biomarkers, such as miRNA and serum Biomarkers can deliver info about the immune response of a body under normal or abnormal conditions.
- Track 5-1Challenges to biomarkers development in Immune system
- Track 5-2Biomarkers discovery in Immunology
- Track 5-3Biomarkers for Early Progressive Inflammatory & Immunological Diseases
- Track 5-4Biomarkers of Disease Pathogenesis
- Track 5-5Biomarkers under autoimmune system
Biomarkers are important tools in drug development and pharmaceutical research. Biomarkers have been recognized by making the drug development process more efficient and have become an essential part of a pharmaceutical and pharmacological research. It is expected that the number of biomarkers will ultimately transition into the clinical laboratory.
The biomarkers demonstrate the dose-response relationships of the drug between changes in biomarkers, the onset of the injury and the severity of the injury corresponding to the progression of the injury.
- Track 6-1Pharmacokinetic Biomarkers
- Track 6-2Pharmacogenomic Biomarkers
- Track 6-3Priorities and needs of PV at different stages of a product life-cycle
- Track 6-4 Pharmacodynamic Biomarkers
- Track 6-5Challenges and opportunities in PV lifecycle management
- Track 6-6Safety surveillance and risk management lifecycle
- Track 6-7Pharmacovigillance in Drug Regulation
Biomarkers play a significant role in oncology that is used in clinical research for risk valuation, differential diagnosis, determination of the nature of tumors, for recognition purposes, to determine the prognosis and dose-response of the drug to the cure. The procedure indicative of the presence of cancer in the body is carried out by means of tools known as cancer biomarkers. There are different types of cancer in which biomarkers have their presentation, such as lung, melanoma, breast, colorectal, pancreas and many more. Biochemically, cancer biomarkers can be DNA, RNA, proteins, peptides, hormones, metabolites and even biological procedures such as apoptosis, angiogenesis or proliferation. Around three key types of cancer biomarkers depending on their clinical use: prognostic, predictive and pharmacodynamics markers.
- Track 7-1Cancer Biomarkers in clinical research
- Track 7-2Diagnosis and treatment
- Track 7-3Lung Cancer
- Track 7-4Cervical Cancer
- Track 7-5Ovarian Cancer
- Track 7-6Breast Cancer
- Track 7-7Prostate cancer
- Track 7-8Testicular Cancer
Biomarkers have numerous uses in pharmaceutical R & D. With the present introduction of high-performance composition, protein and gene arrays and bioinformatics, clinical conclusions like Drug development and selecting the type of treatment can be made proficiently. Still, there is an insufficiency of effective biomarkers to increase the drug development from pre-clinical through all levels of clinical studies. Biomarker in Drug Discovery main lead to the advance of Modified Medicines.
- Track 8-1Biomarker in Drug Design
- Track 8-2Medicine Development in Oncology and Infectious Diseases
- Track 8-3Drug discovery innovation and strategies
- Track 8-4Phenotypic and genomic drug discovery
- Track 8-5Computational chemistry and informatics for drug discovery
Clinical research is a division of social safety science that adopts the well-being and capability (viability) of the solutions, devices, analytical elements and dealing regimes foreseen for human use. These could be used for counterproductive action, management, findings or to calm the side effects of some diseases. Clinical research is special in relation to clinical practice. Collected medications are used in clinical practice, while in clinical research validation is assembled to set up a treatment.
- Track 9-1Bioethics
- Track 9-2Analytic protocols of biomarkers
- Track 9-3Case studies
Clinical trials are tests accomplished in clinical research. Such imminent thoughts of biomedical or social research in human members are planned to answer particular queries regarding biomedical or behavioral mediations, including new medications (eg. new antibodies, medications, dietary decisions, dietary supplements and medical devices) and mediations. Known that need studies and exams. Clinical trials produce information on protection and viability.
- Track 10-1Trends in the globalization of clinical trials
- Track 10-2Strategies for successful globalization of clinical trials
- Track 10-3Globalization of drug development
- Track 10-4Ethical and scientific implications